Drug Trial Radar · NCT05501158
CYP2D6 Genotypes and Breast Cancer Clinical Outcomes in the Indonesian Population
Last checked: Nov 19, 2026Latest source record: Aug 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
150
Actual
Start
Jan 1, 2021
Primary completion
Apr 30, 2024
Study completion Jun 30, 2024
Sponsor
- Lead sponsor
- Nalagenetics Pte LtdIndustry
- Sponsor type
- Industry
- Collaborators
- SJH Initiatives; Universitas Indonesia; MRCCC Siloam Hospitals Semanggi
- First posted
- Aug 15, 2022
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The utilization of tamoxifen is considerably high in Indonesia, with about 170,000 tamoxifen prescriptions filed in 2015. It is metabolized by the enzyme CYP2D6, resulting in its active metabolite, endoxifen, which has been proven to be effective in the prevention and treatment of breast cancer. Studies showed the CYP2D6 gene has more than 100 variants; some of which are linked with reduced drug activity, while others do not have any pathological implications. The metabolizer profile of these variants is generally grouped into Ultra-rapid, Normal, Intermediate, and Poor Metabolizers (UM, NM, IM, and PM, respectively). In our previous study (NCT04312347), the investigators recruited 150 breast cancer patients who were taking adjusted dose of tamoxifen daily based on their CYP2D6 phenotype. Although the investigators have measured the endoxifen level of the patients with adjusted treatment, the clinical outcomes of the study are not yet conclusive.
Conditions
- Breast Cancer
Interventions
TamoxifenDrug
Suggesting an increase in the dose of tamoxifen to those who have suboptimum level of endoxifen due to their genetic variations
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival rateTime frame: 3 year
- Progression Survival rateTime frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MRCCC Siloam Hospitals Semanggi
Jakarta, DKI Jakarta, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.